Comparative Pharmacology
Head-to-head clinical analysis: CORVERT versus SOTYLIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORVERT versus SOTYLIZE.
CORVERT vs SOTYLIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibutilide, a class III antiarrhythmic agent, prolongs atrial and ventricular refractoriness by blocking delayed rectifier potassium current (IKr) and activating slow inward sodium current (INa-S).
Selective beta-1 adrenergic receptor antagonist; also exhibits class III antiarrhythmic activity (potassium channel blockade), prolonging cardiac repolarization and refractory periods.
1 mg intravenously over 10 minutes; repeat once after 10 minutes if conversion to sinus rhythm not achieved. Maximum total dose: 2 mg.
Initial: 80 mg orally twice daily. May increase every 2-3 days in 40-80 mg increments up to 240-320 mg/day. Maximum: 320 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 6 hours (range 2–12 hours) in patients with normal renal function. Prolonged in renal impairment (up to 16 hours in severe impairment).
Terminal elimination half-life is 12-16 hours in patients with normal renal function; can extend up to 30-40 hours in renal impairment, requiring dose adjustment.
Renal (approximately 82% of total clearance), with about 18% biliary/fecal elimination. Mostly unchanged drug and metabolites.
Primarily renal excretion of unchanged drug; 85-90% eliminated unchanged in urine, with the remainder via feces (<5%) and minimal biliary excretion.
Category C
Category C
Antiarrhythmic
Antiarrhythmic